IMEXF - Imagin Medical Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0520
-0.0033 (-5.97%)
As of 2:32PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.0553
Open0.0550
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0520 - 0.0600
52 Week Range0.0440 - 0.1700
Volume31,320
Avg. Volume37,767
Market Cap8.438M
Beta (3Y Monthly)2.99
PE Ratio (TTM)N/A
EPS (TTM)-0.0560
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Imagin Medical Reports Progress in i/Blue™ Imaging System Functional Unit Development Phase

    Imagin Medical (CSE:IME) (IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported continued progress toward verification of its i/Blue functional prototype product. At the recent American Urology Association Meeting, Imagin held private focus groups with leading urologists to demonstrate the first i/Blue functional prototype product. Input from these meetings, and the overwhelmingly positive feedback from the physicians, have been used to finalize the i/Blue product’s user needs, which have been integrated into its design specification, moving the functional phase of development forward.

  • GlobeNewswire24 days ago

    Imagin Medical Announces Stock Option Grant

    VANCOUVER, British Columbia and BOSTON, June 24, 2019 -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the “Company”) announced that, under.

  • GlobeNewswirelast month

    Imagin Medical Reports Fiscal 2019 Second Quarter Results

    Imagin Medical (CSE:IME) (IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported financial results for the three months ended March 31, 2019. All amounts, unless otherwise specified, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards (IFRS). Imagin completed the Proof of Concept Phase of the redesigned i/Blue™ Imaging System’s Control Unit, and subsequently reached the first step of another major product development milestone with the completion of assembly of the system’s Functional Unit.

  • GlobeNewswirelast month

    Imagin Medical to Report Second Fiscal Quarter 2019 Financial Results on June 11, 2019 – Conference Call to Follow

    VANCOUVER, British Columbia and BOSTON, June 03, 2019 -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”), an.

  • GlobeNewswire3 months ago

    Imagin Medical Welcomes World-Renowned Bladder Cancer Expert Dr. Ashish M. Kamat to Its Scientific Board of Advisors

    Imagin Medical (CSE:IME) (IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced that Dr. Ashish M. Kamat has joined its Scientific Advisory Board. Dr. Kamat has been named by Expertscape as the world’s top-rated expert in urinary bladder neoplasms. Dr. Kamat has extensive experience with cystoscopic procedures, has been a principal investigator for multiple oncology and urology clinical studies for both drugs and devices, and has been involved in blue light cystoscopy studies since 2007.

  • GlobeNewswire4 months ago

    Imagin Medical Completes Assembly of i/Blue™ Imaging System Functional Unit

    Imagin Medical (CSE:IME) (IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced that it reached the first step of a major product development milestone with completion of the i/Blue Imaging System’s Functional Unit, which has successfully met the Company’s pre-established performance expectations. Following the typical product development path for a new medical technology, the Company is working to move the i/Blue Imaging System through various progressive stages: original design, proof of principle prototype, functional system, pilot production, product validation and, finally, realized product for commercialization.

  • GlobeNewswire5 months ago

    Imagin Medical Reports Fiscal 2019 First Quarter Results

    Imagin Medical (CSE:IME) (IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported financial results for the three months ended December 31, 2018. All amounts, unless otherwise specified, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards (IFRS). Completed, via Imagin’s opto-electronic design firm, Optel, Inc., the Proof of Concept Phase of the redesigned i/BlueTM Imaging System’s control unit and validated the performance of the light source and imaging modules.

  • GlobeNewswire5 months ago

    Imagin Medical to Report First Fiscal Quarter 2019 Financial Results on February 27, 2019 – Conference Call to Follow

    VANCOUVER, British Columbia and BOSTON, Feb. 19, 2019 -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”), an.

  • GlobeNewswire6 months ago

    Imagin Medical to Present at Noble Capital Markets’ 15th Annual Investor Conference

    Imagin Medical (CSE:IME) (IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”), an emerging leader in the development and commercialization of advanced medical imaging technologies, announced today management will present an update on the Company’s business at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference, on Tuesday, January 29, 2019, at 12:00 p.m. Eastern Time at the W Hotel in Fort Lauderdale, FL. A webcast of the presentation will be available the following day on the Company’s website at www.imaginmedical.com in the ‘Investors’ section, and will be archived for 90 days. The Company believes its technology will radically improve physicians’ ability to detect cancer with minimally invasive endoscopes, improving their ability to visualize, identify and remove cancerous cells.

  • GlobeNewswire6 months ago

    Imagin Medical Posts New Presentation on Its Website

    Imagin Medical (CSE:IME) (IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced that, ahead of its planned meetings with members of the investment community over the coming weeks, it has made its updated corporate presentation available on the Company’s website. The presentation can be accessed by visiting the Investors section of www.imaginmedical.com. The Company believes its technology will radically improve physicians’ ability to detect cancer with minimally invasive endoscopes, improving their ability to visualize, identify and remove cancerous cells.

  • GlobeNewswire7 months ago

    Imagin Medical Reports Fiscal Year End 2018 Results

    Imagin Medical (CSE:IME) (IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported financial results for the year ended September 30, 2018. All amounts, unless otherwise specified, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards (IFRS).

  • GlobeNewswire7 months ago

    Imagin Medical Announces Results Of Annual Meeting Of Shareholders

    All of the matters put forward before the shareholders, as set out in the Company's management information circular dated November 15, 2018, were approved by the requisite majority of votes cast at the Meeting.  Specifically, De Visser Gray LLP was appointed as the Company’s auditors for the ensuing year, and Jim Hutchens, Dr. Robin Atlas, Kenneth Daignault, John Vacha and Chris Bleck were appointed as directors. The biographies of all members of the Board are available on the Company’s website at https://imaginmedical.com/directors/.

  • GlobeNewswire8 months ago

    Imagin Medical Comments on Recent Promotional Activity Pursuant to OTC Markets Request

    Imagin Medical Inc. (CSE:IME) (IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) wishes to make the following statements regarding certain market activity surrounding its common shares (the "Common Shares"). On November 26, 2018, the Company was notified by the OTC Markets about certain promotional emails distributed in relation to its Common Shares from November 23 through November 26, 2018.  Based on a review of the recent trading activity in the Common Shares, it appears that the effect of these promotional emails may have been an increase in the volume of Common Shares traded on November 26, 2018 on the OTCQB.  It is not, however, possible to accurately quantify this effect, and there was virtually no change in the closing price of the Common Shares on November 26, 2018.

  • GlobeNewswire9 months ago

    Imagin Medical Receives Approximately $1 Million From Exercise of Warrants

    Imagin Medical (CSE:IME) (IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) announced today that it has received proceeds of CA$954,854 as a result of the exercise of 9,533,540 previously issued common share purchase warrants (the “Warrants”). The exercised Warrants were issued in connection with the Company’s public offering of units completed in two tranches in October 2017 and were set to expire on October 5, 2018 and October 16, 2018, respectively.  The exercise price of 9,508,540 of the Warrants was $0.10 and 25,000 of the Warrants was $0.16. Following the exercise of these Warrants, Imagin continues to have an aggregate of 22,940,277 share purchase warrants outstanding, with expiry dates ranging from November 2018 to April 2020.